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The socio-economic impact of Alzheimer′s disease
(AD) and other dementias is enormous, and the
potential economic challenges ahead are clear
given the projected future numbers of individuals
with these conditions. Because of the high preva-
lence and cost of dementia, it is very important to
assess any intervention from a cost-effectiveness
viewpoint. The diagnostic criteria for preclinical AD
suggested by the National Institute on Aging and
Alzheimer’s Association workgroups in combina-
tion with the goal of effective disease-modifying
treatment (DMT) are, however, a challenge for
clinical practice and for the design of clinical trials.
Key issues for future cost-effectiveness studies
include the following: (i) the consequences for
patients if diagnosis is shifted from AD-dementia
to predementia states, (ii) bridging the gap between
clinical trial populations and patients treated in
clinical practice, (iii) translation of clinical trial
end-points into measures that are meaningful to
patients and policymakers/payers and (iv) how to
measure long-term effects. To improve cost-effec-
tiveness studies, long-term population-based data
on disease progression, costs and outcomes in
clinical practice are needed not only in dementia
but also in predementia states. Reliable surrogate
end-points in clinical trials that are sensitive to
detect effects even in predementia states are also
essential as well as robust and validated modelling
methods from predementia states that also take
into account comorbidities and age. Finally, the
ethical consequences of early diagnosis should be
considered.
Keywords: Alzheimer’s disease, clinical trials, demen-
tia, diagnosis, health economics.
Introduction
Today, about 36 million people worldwide suffer
from Alzheimer′s disease (AD) and other dementias
[1]. This figure is projected to more than double by
2030 (65 million) and reach about 115 million in
2050 unless there are major improvements in
prevention and/or cure. This increase will be
greatest in low- and middle-income countries
(LMICs) where it will be roughly exponential, whilst
in high-income countries (HICs), the increase will
be more linear.
Symptomatic treatment of AD with acetylcholine
esterase inhibitors and memantine has been avail-
able since the 1990s, but no cure or disease-
modifying treatment (DMT) for AD is available
today, despite extensive research in this area.
Epidemiological research has suggested several
risk and protective factors for dementia, giving
hope for prevention approaches that modulate the
risk of dementia including lifestyle factors such as
more physical exercise and weight reduction and
medical factors such as hypertension, elevated
cholesterol and diabetes. These provide potential
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opportunities to reduce the risk of dementia at
least partially [2], and there is some evidence to
indicate that this is already happening based upon
reduced age-related incidence and prevalence rates
[3, 4].
The socio-economic impact of dementia disorders
is enormous. In 2010, the worldwide societal costs
were estimated at US$ 604 billion, which consti-
tutes approximately 1% of the aggregated global
gross domestic product [5, 6] (Fig. 1) with the
greatest proportion of costs from HICs. There is a
huge impact of informal care throughout the world,
particularly in LMICs where resources in the social
care sector are scarce. The potential economic
challenges ahead are clear given the projected
future numbers of individuals with dementia.
However, the challenges vary in different parts of
the world; in HICs, the challenge seems to be
funding of long-term care, whereas in LMICs,
establishing a social care sector is most important.
The greatest challenge for all is to develop effective
management, treatment and cure (where possible).
Given the high prevalence and cost of dementia, it
is important to assess any such intervention from a
cost-effectiveness viewpoint.
Any type of intervention/treatment includes a
diagnostic process. One of the key controversies
has been the magnitude of benefit conferred to
individuals through early diagnosis and access to
clinical and care services in the absence of DMTs.
Whilst some view the benefits as limited, others
argue for offering early diagnosis of AD, highlight-
ing the value of information, family support, care
planning and signposting and the importance for
individuals of being able to take control of deci-
sions regarding their own treatment and care
whilst they retain capacity (given the assumption
that the diagnosis is correct) [7]. The true value of
these interventions and other aspects of service
support are difficult to determine from the cur-
rently available evidence. A substantial and cost-
effective positive impact on quality of life was
demonstrated in an open study of memory clinic
services, but this finding was difficult to interpret
in the absence of a control group [8]. By contrast,
randomized controlled trials (RCTs) focusing on
specific aspects of service delivery such as infor-
mation, education, signposting and case manage-
ment have delivered benefits with only a small
standardized effect size [9], indicating difficulty in
testing whether the interventions are cost-effective.
Although difficult to conduct, cluster RCTs (pref-
erably several in various settings and populations)
to examine the benefits associated with early
diagnosis supported by a comprehensive service
model are essential to inform planning and service
development.
A great challenge in differential diagnosis of
dementia or predementia subtypes [i.e. preclinical,
mild cognitive impairment (MCI) or early dementia]
is that there is no single test or diagnostic tool that
confirms the diagnosis. An AD diagnosis is, for
example, based on a comprehensive but varying
mixture of clinical examinations, laboratory,
genetic and neuropsychological tests and analyses
of biomarkers [e.g. cerebrospinal fluid (CSF) mark-
ers and different imaging methods].
The previously [10] and recently by the National
Institute on Aging and Alzheimer’s Association
workgroups [11–13] suggested new diagnostic cri-
teria for preclinical AD, AD-MCI and AD-dementia
include both recommendations for clinical practice
without access to advanced diagnostic tools and
recommendations for research. Although the
research criteria include the use of biomarkers, it
was nevertheless concluded by the workgroups
[11–13] that much validation work is still needed.
Furthermore, much interest today in predementia
diagnosis of AD (preclinical and/or MCI) is linked
to the hope for effective DMT. If powerful DMTs
become available, being able to recognize AD cases
at a very early stage (i.e. in the preclinical phase)
would represent enormous progress both for
patients with subtypes of predementia and for
their families. However, at present without the
availability of DMTs, the arguments for diagnosis of
preclinical AD or MCI-AD are for many reasons
more complex and controversial. Here, we will
discuss this issue from a health economic view-
point. Although the focus will be on AD, it is









Direct social care cost
Fig. 1 Estimated global aggregated costs of dementia
care in 2010 in different income groups according to the
World Bank [6].
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sometimes not possible or meaningful to separate
AD from other dementias. Thus, we may consider
the preclinical phase and MCI either separately or
combined as predementia states. These terms are
used to identify the implications of the new diag-
nostic criteria. However, from an epidemiological
viewpoint, the concept ‘at risk’ rather than ‘pre-
clinical’ might be more appropriate as the latter
supposes that the prediction will be accurate even
though (as noted herein) a substantial proportion




Cost of illness (COI) studies, such as the estimate
of global costs [14], are descriptive and cannot be
used to specify allocations of resources for treat-
ment. COI studies can describe how costs are
distributed amongst payers and how costs change
over time. In dementia care, it is already known
that the most important cost drivers are long-term
institutional care and the societal value of informal
care. Another conclusion from COI studies is that
we are primarily seeing the ‘wrong’ type of costs;
costs of dementia mainly comprise resources lost
due to disease or resources used to cope with the
consequences of disease. Only a small fraction of
resources are spent on activities to prevent or delay
disease onset and progression.
Cost-effectiveness
Cost-effectiveness analysis is a tool that is used to
assess efficiency in resource allocation and to
guide decisions on the introduction and use of
new technology [15]. It has a formal place in the
process for assessing new pharmaceutical prod-
ucts in a number of countries and is used infor-
mally across most markets.
Reports of empirical cost-effectiveness studies are
rare. In a systematic review of dementia by the
Swedish health technology assessment institute
SBU [16], only five such studies were identified in
which drugs for AD were analysed. For nonphar-
macological interventions, the situation was the
same – only a few studies were identified. On the
other hand, more economic evaluations based on
simulations have been reported.
Implications of the new diagnostic criteria
From a health economic viewpoint, any diagnostic
process raises questions: can cost-effectiveness of
diagnostics per se be discussed (has a diagnosis
alone any value?) or must there be a link between
the diagnosis and some type of treatment/inter-
vention/other outcome?
In AD diagnosis, there are several potential path-
ways before a diagnosis is established and the list
of diagnostic tools in Table 1 reflects the options
that are recommended by, for example, the Euro-
pean Federation of Neurological Societies [17].
Different tools are available and their accuracy,
costs, optimum number and sequence of use can
be considered. If diagnosis of AD is to move from
AD-dementia to predementia AD states (such as
AD-MCI), the first two diagnostic options shown in
Table 2 [primary care (PC) alone and PC plus
specialist clinical examination only (SCE)] are
unlikely to be appropriate. When a set of tools is
introduced into the diagnostic process, there is
considerable variation in the costs (as seen in
Table 2), according to which and how many tools
are used.
Additionally the validity and reproducibility of
tools are important. Any diagnostic tool [clinical
examination, neuropsychological testing, magnetic
resonance imaging (MRI) or CSF biomarkers]
with a potential important additive value for the
diagnosis of AD should therefore be used in a
standardized way. Harmonization of protocols
decreases the need for replication and can reduce
the diagnostic costs in routine clinical practice.
Table 1 The ability of different diagnostic tools to detect different levels of cognitive impairment
Clinical examination Neuropsychology PET MRI CSF
AD-dementia xx xxx xx xx xx
AD-MCI x xx xx xx xx
Preclinical AD 0 x x x xx
AD, Alzheimer’s disease; MCI, mild cognitive impairment; PET, positron emission tomography; MRI, magnetic resonance
imaging; CSF, cerebrospinal fluid biomarkers; 0, not possible; x, fair; xx, good; xxx, very good.
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However, harmonization is not usually achieved as
addressed by the European Alzheimer′s Disease
Consortium [18] and the European Alzheimer’s
Disease Neuroimaging Initiative [19]. It remains
unclear whether it is possible to identify an optimal
diagnostic pathway, which is generalizable across
populations. The marginal cost for each additional
new case that is identified when a new tool is added
to the diagnostic process may be high, but such an
analysis has yet to be reported. Such studies are
urgently needed and require a gold standard
method with an evaluation of the benefits not only
of finding new cases but also of avoiding false-
positive (FP) and false-negative (FN) cases when
more tools are included in the process.
The diagnostic process when AD is suspected also
takes time, from the first awareness of the possi-
bility and symptoms to initial contact with health
care (often PC) and to the day of diagnosis. If this
diagnostic uncertainty shifts from dementia to
predementia states, the time window from early
diagnostic procedures to a definite diagnosis (or a
statement – at least temporarily – that AD is not
suspected) may be several years during which time
the person must live with this uncertainty and will
be very likely to require repeat clinic visits and
undergo further investigations. This period of
uncertainty and medicalization may lead to addi-
tional stress and loss of quality of life during
possibly the last period of an older person′s life.
In individuals at an earlier stage of life, this
uncertainty and medicalization may also lead to
losses in terms of sick leave and production. Being
labelled as ‘being at increased risk of AD’ may have
potential negative implications for individuals; the
impact of this is unknown at present as current
evidence is based on informing individuals who
have volunteered for research as a result of their
family history. To inform this debate, we will need
to know from the population how individuals will
respond to knowledge of risk over prolonged peri-
ods and be able to provide them with evidence of
how accurate that risk prediction might be (i.e. in
how many individuals the prediction of increased
risk will be incorrect). How this period of uncer-
tainty should be valued in economic terms is
unclear. And if science storms ahead but is not in
tandem with society, this might have economic
consequences not only for individuals but also for
society.
Besides the psychological consequences of an early
diagnosis, the diagnostic methods themselves may
have (potential) side effects. For example, if a large
number of individuals undergo lumbar puncture
(for CSF sampling), computed tomography (CT),
positron emission tomography (PET) (including the
newly available amyloid imaging techniques) or
MRI investigations as a consequence of the intro-
duction of DMT with a need for comprehensive
diagnostics, there may be a significant number of
side effects (perhaps particularly with CSF sam-
pling) with economic consequences that need to be
considered.
The age of the target population also needs to be
taken into account. Even if a ‘pure AD’-type pathol-
ogy contributes to the cognitive decline in the ‘oldest
old’ (i.e. ≥85 years old), based on our knowledge
of the underlying pathology, it is likely that comor-
bid conditions are involved [20]. Figures for the
sensitivity and specificity of new investigations as
Table 2 Examples of different diagnostic pathways when
AD is suspected
Diagnostic


















Dia, diagnostic pathway, PC, primary care (includes
clinical examination, laboratory tests, computed tomog-
raphy scan and the Mini-Mental State Examination);
SCE, specialist clinical examination (only); MRI, magnetic
resonance imaging; CSF, cerebrospinal fluid; NP, neuro-
psychological examination; PET, positron emission
tomography.
*US$ 1  7 SEK.
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well as the positive (PPVs) and negative predictive
values (NPVs) are derived from selected popula-
tions from specialized memory clinics that are
mostly younger than those with the ‘usual’ demen-
tias seen in the oldest old [21]. Thus, the potential
benefits of diagnosis and the magnitude of treat-
ment benefits need to be considered and weighed
against the side effects and burden. From a cost-
effectiveness viewpoint, this means that the costs
of diagnosis and treatment may not be offset
sufficiently as the benefits in terms of outcome
may be limited. For the oldest patients, other care
strategies may be more cost-effective. However,
this is not an argument for fixed age restrictions in
general as individuals′ situation and health status
should always the most important criteria as well
as their likelihood of benefit from treatment, given
their age and comorbidities.
One important question therefore is whether we
should aim to diagnose preclinical AD, AD-MCI or
AD-dementia. In terms of consequences, we must
include not only all true-positive (TP) and true-
negative (TN) cases (based on a gold standard and
in relation to diagnostic criteria), but also FP and
FN cases. What are the trade-offs in terms of cost-
effectiveness if the diagnosis is linked to treatment
(i.e. benefits for TPs but disadvantages for non-
treated FNs and both disadvantages and side
effects for treated FPs)? Even if it is possible to
calculate the costs for the different diagnostic
pathways and the cost for each diagnosed TP case
(and estimate the cost-effectiveness of treatment
versus no treatment/usual care) and TN case, how
should the consequences for FPs and FNs be
valued. When most diagnoses of AD in clinical
practice were for mild-to-moderate disease, the
magnitude of this problem was not so great;
however, if the diagnostic target group is moved
from AD-dementia to AD-MCI (or even further to
preclinical AD), particularly if a screening policy or
systematic case finding is recommended, the sit-
uation will become very challenging, as illustrated
in Table 3. The major problem will be the risk of
FP cases as indicated by the PPVs. As mentioned
above, at the individual level, there is an uncer-
tainty about the classification of a person′s risk of
developing AD-dementia. Follow-up confirms
whether or not classifications in terms of TP, TN,
FP and FN were correct. It is difficult to estimate
the consequences of living with a FP diagnosis of
AD for several years from a cost-effectiveness
viewpoint (the denominator in the incremental
cost-effectiveness ratio ICER).
Is this situation unique for AD? Perhaps not, but a
shift in the diagnostic spectrum from AD-dementia
to predementia states will probably make the risk
of FPs greater, because the diagnostics of AD is not
straightforward.
As most studies on sensitivity and specificity are
undertaken in highly specialized clinics (mainly
university clinics with a high ‘prevalence’ of AD in
the target population and a high level of resources),
we cannot predict what will happen if diagnosis on
a large scale moves to PC, and specialist clinics
become a scarce resource. If effective DMTs
become available, there may be demands for very
early diagnosis (including screening). Then, sensi-
tivity and specificity figures between, for example,
80 and 90% will be problematic (Table 3). The
nature of the testing methods is important. Differ-
ent types of screening can be used, such as mass
screening (e.g. all persons 65 or older every
5 years), opportunistic screening (e.g. any person
who enters any healthcare centre will be offered
cognitive testing) or risk screening (e.g. only genetic
risk groups). The World Health Organization (WHO)
has recommended criteria for screening [22] (see
Box 1), and it seems obvious that currently any
screening programme for AD generally is problem-
atic and hardly recommendable today.
However, if effective DMTs for AD were available,
one solution may be a two-step approach, as
shown in Table 3, with the aim of increasing the
probability of cases with the disorder in the target
population [16]. The first step may reflect activities
in PC and the second step at the specialist level. In
the Swedish SveDem registry, the cost of diagnostic
activities in PC (including a clinical examination, a
basic laboratory battery of tests, the Mini-Mental
State Examination or similar and in many cases CT
scanning of the brain) was 6800 SEK (approxi-
mately US$ 1000 or €800), and in specialist care
(with varying use of MRI, PET and CSF and
neuropsychological testing), the average cost was
11 700 SEK [23]. As well as the lower risk of FPs,
there may also be cost savings in using PC as the
first-level filter for diagnosis, but the risk of course
is of FNs in PC.
Implications of new diagnostic criteria for clinical trials
Following the introduction of the new diagnostic
criteria, the design of clinical trials will be chal-
lenging. Sample size estimates need to be con-
sidered. For economic evaluations, this has two
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implications; first for the efficacy results per se
(which are crucial for modelling) and secondly for
the within-trial analysis of resource utilization
and cost-effectiveness. An experience from the
studies where within-trial results on resource
utilization and costs have been evaluated
[24–27] shows that they are underpowered for
economic evaluations. If there is a shift in trials
from populations with AD-dementia to those with
predementia states, there will be a need for
sample size estimates for both efficacy and cost-
effectiveness evaluations, probably also with a
need for larger study populations and longer
duration of trials. We will need better background
data on both costs and outcomes in predementia
states. Similar to diagnosis where several
tools are needed, there is an interest in analysing
the cost-effectiveness of combined treatment
approaches (such as drug treatment with social
support programmes) [28].
Implications of new diagnostic criteria for clinical practice
The introduction of new diagnostic criteria into
clinical practice in parallel with the development of
DMTs may lead to two extreme scenarios: (i)
successful implementation of predementia diagno-
sis of AD (preclinical and/or AD-MCI), but no
availability of DMTs due to trial failures; or (ii)
availability of an effective DMT, but very limited
diagnostic infrastructure to identify individuals
who are suitable for treatment (i.e. in any window
of modifiability).
To a varying extent, most patients with AD-demen-
tia are diagnosed late or not at all [29]. Even if
either of the extreme scenarios is unlikely to occur,
we are now facing a new challenge in the manage-
ment and diagnosis of AD. Many trials have failed,
but there are still several DMT approaches in the
pipeline. There may be demands of and possibili-
ties for predementia AD diagnostics (with all the
problems mentioned above). If the goal of diagnos-
tics is to diagnose dementia, and the type of
dementia, PC can provide the first level in the
diagnostic process (although this opportunity is
often not used in an optimal way). If the aim is
predementia diagnosis, the two-step approach
seems appropriate where PC is the filter before
advanced specialist diagnosis. To some extent, this
is the way it is organized today, but if effective
DMTs become available, the magnitude of the
potential target population will be large and there
will be a high demand for diagnosis and care. Some
type of infrastructure for early diagnosis would
need to be established with PC as a filter. As the
situation is today (WHO criteria; risk of FPs), this
does not imply the need for mass screening but
how to manage the potential increased demand
must be considered. If DMTs are developed, it is
also important to identify the most cost-effective
diagnostic pathway at the specialist level (the
Table 3 Examples of how different levels of prevalence, sensitivity and specificity affect the PPV and NPV under various
conditions







Incident AD (1.6% of target population)
PPV 6.3 13.0 24.1 62.3
NPV 99.6 99.8 99.9 99.9
AD-MCI or prevalent AD (7.4% of target population)
PPV 24.2 41.9 60.3 88.8
NPV 98.0 99.1 99.6 99.9
Two-step approach (prevalence 25% of target population)
PPV 57.1 75.0 86.4 97.1
NPV 92.3 96.4 98.3 99.7
Memory clinic (assumed prevalence 50%)
PPV 80.0 90.0 95.0 99.0
NPV 80.0 90.0 95.0 99.0
AD, Alzheimer’s disease; MCI, mild cognitive impairment; PPV, positive predictive value; NPV, negative predictive value.
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optimum number and most effective sequence of
tests) as illustrated in Table 2.
Another practical consequence of effective DMTs is
the potentially large number of predementia AD
cases (TPs and FPs) that are identified and need
support, treatment and ongoing care. The DMTs
that are currently being considered (such as vac-
cination) have security and monitoring demands
that makes a referral back to PC unlikely. Thus,
many challenges can be anticipated including
memory clinic visit volumes and equitable access
to therapies. There will be prioritizing problems for
decision-makers when demands occur for alloca-
tion of resources to memory clinics (e.g. versus
cancer clinics). Another consequence of scarce
resources might be a re-allocation away from care
of patients with severe dementia to those with an
early diagnosis, given the assumption that DMT
will be successful. In such a situation, we need to
have good instruments for cost-effectiveness analy-
ses as a support in decision-making.
Current understanding of risk based on observa-
tional studies supports prevention through pri-
mary prevention and optimal management of
vascular risk and is supported by projections from
modelling of the population impact of such mea-
sures [30, 31]. Prevention activities in PC and wider
society should be emphasized beyond the usual
prevention of cardiovascular ill health [32].
A special situation may occur, for example, in the
case of rare familial AD where gene therapy may be
possible [33]. Even if individual costs for the
diagnostics and treatment of rare diseases may
be high, the total societal costs will be low because
of the small number of affected persons, and thus,
high costs may be justified if effective diagnostics
and treatment become available.
Implications of new diagnostic criteria for reimbursement
Patients with AD receive care and support from
many different formal and informal sectors of
society. In HICs and in early disease states
support is mainly received from the healthcare
system (PC and specialist care) but, the social
care sector (e.g. home or day care and long-term
care) becomes more important as the disease
progresses. Informal care makes an important
contribution throughout the disease course. Inter-
ventions may have an impact on resource use and
costs in different sectors, but it is unlikely that
the benefits of interventions will be distributed
similarly (both in terms of magnitude and time)
compared to the benefits. At one extreme, the
costs occur in one sector, but the benefits in
another. If for example a very effective DMT is
introduced, the health care sector will bear the
costs for diagnosis and treatment and its reim-
bursement but most of the benefits will be seen
later in the course of AD in the social care sector.
Such a scenario was shown in a recently pub-
lished hypothetical model [34]. Even if the inter-
vention is cost-effective from a societal viewpoint,
the imbalance is a problem (and may be labelled
Box 1
Classic World Health Organization screening
criteria [65]
1 The condition sought should be an important
health problem.
2 There should be an accepted treatment for
patients with recognized disease.
3 Facilities for diagnosis and treatment should
be available.
4 There should be a recognizable latent or early
symptomatic stage.
5 There should be a suitable test or
examination.
6 The test should be acceptable to the
population.
7 The natural history of the condition, including
development from latent to declared disease,
should be adequately understood.
8 There should be an agreed policy on whom to
treat as patients.
9 The cost of case finding (including diagnosis
and treatment of patients diagnosed) should
be economically balanced in relation to
possible expenditure on medical care as a
whole.
10 Case finding should be a continuing process
and not a ‘once and for all’ project.
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as imperfect or even as a perverse incentive).
Because an effective DMT is likely to be much
more costly than current treatment (making reim-
bursement crucial) and a large number of indi-
viduals from an equity viewpoint will demand
care, it is a challenge to avoid or regulate emerg-
ing imbalance.
Key methodological issues
Bridging the gap between clinical trial populations and patients to be
treated in clinical practice
Study populations in AD clinical trials are in
general younger and healthier with fewer concur-
rent comorbidities than AD populations in epide-
miological studies and in clinical practice [35]. The
decline in cognition may be faster in younger AD
patients but the decline in functional outcomes
may be slower, compared with older patients.
There are different ways to handle this situation.
To make a comprehensive judgement of the cost-
effectiveness of interventions in AD, it is necessary
to synthesize the information and the conclusions
need to be based on several types of inputs.
Therefore the aim cannot be to identify the single
ultimate design; rather it is to identify a number of
designs that may be useful in discussions of cost-
effectiveness (Table 4).
One approach is to change the inclusion strategy in
clinical trials in order to better reflect the overall
population (older and with more comorbidities) so
that trial results are more generalizable. At first
glance this approach seems feasible, but it is also
risky. If the aim is to test disease-modifying effects
on AD, it is crucial that the target population in a
trial indeed suffers from pure AD. A population
that in current clinical practice may be considered
to have AD is probably composed of individuals
with several conditions that may influence cogni-
tion together with an AD process [36], making
intervention effects difficult to detect. However, the
results will be more generalizable to the whole
population.
The results from epidemiological studies highlight
the influence of vascular factors in AD. It is well
known that the proportion of patients considered
to have AD or vascular dementia changes with age
(the older the individual, the more the cardiovas-
cular contribution appears to be). However, the
findings from epidemiological studies also indicate
that vascular issues may be involved in the AD
process and that comorbidities are mainly vascu-
lar, therefore this discussion of inclusion strategies
in trials reflects the controversy of what is AD
(which is not the aim of this review). In the
Kungsholmen project, when dementia cases were
re-evaluated and re-classified in light of the new
epidemiological results on risk factors [36], the
proportion of pure AD cases without vascular
components was only 41% and ‘mixed AD’ was
more common; this finding was substantiated by
Table 4 Advantages and disadvantages of different study designs from a health economic viewpoint
Design Advantages Disadvantages
Classic RCT High internal validity Selected populations; rarely powered for economic
evaluations; short trial duration
Pragmatic RCT Study population reflects
clinical reality
Rarely powered for economic evaluations; not
necessarily blinded
Registry Large samples; long follow-up Not controlled; no predefined hypotheses; heterogenous
study populations; lack of important data (informal care);





both AD and non-AD cases
Not controlled; varied quality of diagnoses; may be few
cases in cohort studies
Simulation High external validity; different
scenarios
testable in sensitivity analysis;
long-term effects
Not empirical in long-term estimates; inputs of varying quality;
assumptions crucial
AD, Alzheimer’s disease; RCT, randomized controlled trial.
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the results from population-based clinicopatholog-
ical studies [37].
Another completely different strategy is to further
identify pure AD patients (e.g. with biomarkers) to
enrich the target population. If the amyloid and/or
tau hypotheses are true and can be confirmed with
DMT trials for pure AD, it is likely that the DMT will
only be effective in a small population of individ-
uals who are younger than those considered to
have mixed AD, Thus the results can be general-
ized to a small population (but how small remains
unclear), making it easier to justify cost-effective-
ness of DMT.
Another approach is epidemiological and registry
studies. Although from an evidence-based medi-
cine perspective these types of studies are in
general rated lower than RCTs (for example, the
non-controlled design, risk of selection bias and
the chicken and egg discussion for epidemiological
studies and registries), they have some obvious
advantages. The number of individuals included in
registries is generally high and may better reflect
the general population than participants in RCTs.
Registries can be characterized as (i) care registries
(for example recording hospitalizations, visits to
open care, death certificates and drug use) and (ii)
diagnosis/syndrome-specific (or similar) quality of
care registries. Not all registries include data that
are useful for cost-effectiveness analyses, but
patient registries and linked administrative claims
and electronic medical records may provide infor-
mation about costs and certain consequences of
care and management (such as institutionalization
and survival) [38]. In Sweden the dementia regis-
try, now including data from more than 25 000
individuals with dementia, has been used for
estimates of diagnostic costs [23]. In addition to
these general disadvantages with registries, there
are always problems with missing data that are
crucial from a cost-effectiveness viewpoint (for
example lack of data from informal care and
relevant outcome measures).
In epidemiological studies the follow-up periods
are in most cases much longer than in RCTs (even
if the intervals between follow-up are longer) and it
may in epidemiological studies be possible to
identify patient groups that are or are not on some
kind of treatment. Epidemiological studies usually
include a comprehensive set of variables that
are useful for different regression/covariate test-
ing. Thus, despite the potential to be useful in
treatment discussions, epidemiological studies
include data that are crucial for estimates of
progression rates (that can be used in models). If
epidemiological studies also include data about
resource use, they can be used for estimates of cost
and as inputs in cost-effectiveness models. Com-
bining the control data from trials and integrating
them with the findings from register and popula-
tion cohorts will be a powerful approach in future.
Through simulation models it is possible to trans-
late efficacy data observed in a clinical trial sample
to long-term outcomes for a broader population in
clinical practice. This is established practice for the
evaluation of new pharmaceutical products; deci-
sion-making bodies in several countries accept or
require evidence from models for the pricing and
reimbursement of new pharmaceutical products.
Simulation models based on clinical trial data have
been developed for clinical AD-dementia [39].
Recent systematic reviews have shown that effects
on mortality and time to institutionalization are
crucial for cost-effectiveness estimates [40, 41].
However, models focusing on the presymptomatic
or MCI stages of AD are rare. Modelling the cost-
effectiveness of interventions in the predementia
stages of AD requires longitudinal data on progres-
sion through the disease stages, resource utiliza-
tion and quality of life, all of which are rarely
available at present. In a model of a hypothetical
disease-modifying intervention in AD, the inter-
vention was not found to save costs in the basic
option with a prolonged effects on survival, but if it
was assumed that there were no such differences
in survival, the intervention was cost neutral [34].
Translating clinical trial end-points into measures that are
meaningful to patients and policymakers/payers
Cognition, activities of daily living (ADL) capacity,
behavioural and psychological symptoms in
dementia and global/stage instruments are the
traditional and most frequently used efficacy out-
comes in clinical trials in AD.
Although quality of life (in a wide context) is
regarded as a relevant (or perhaps the most rele-
vant) outcome of treatment of AD for patients as
well as for carers, it is seldom used; when used,
quality of life has not or has rarely been shown to
be significantly affected [16, 41, 42]. Assessment of
quality of life is complex. Instruments may be
diagnosis specific such as the Dementia Quality of
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Life instrument (DQoL) [43], Quality of Life-Alzhei-
mer’s Disease (QoLAD) [44], DEMQOL [45] and, in
late-stage dementia, The quality of life in late-stage
dementia (QUALID) [46] or generic tests such as
the Short Form (SF) series [47] or WHOQOL [48]. In
cost-effectiveness studies, particularly in model-
ling, quality-adjusted life-year (QALY) instruments
are frequently used such as EQ5D/EuroQol [49],
Health Utilities Index (HUI) [50], 15D [51], SF-6D
[52] and quality of well-being (QWB) scale [53].
QALYs reflect both quantity and quality of life [54,
55] and the advantage is that there are opportuni-
ties for comparisons with other diseases. However,
the use of QALYs is not without controversy [56].
Chronic incurable progressive disorders are rela-
tively misfavoured when compared with surgical
treatment, for example cataract or hip replacement
surgery. Health utility figures may also be difficult
to interpret – what does a figure such as 0.546
really mean?
If predementia states are included in cost-effec-
tiveness studies of AD in which QALYs are used,
more studies to analyse utilities in these states are
needed. It is not clear whether the scales we use
today are sensitive enough to detect meaningful
changes in quality and quantity of life. Only one
study included utility figures for different stages in
the Clinical Dementia Rating (CDR) scale (includ-
ing the CDR stage 0.5, which is rather similar to
MCI) [57]. The WHO often uses disability-adjusted
life-years (DALYs) [58] instead of QALYs, where the
focus is on disability and not quality of life.
Family members of individuals with AD have
several roles, besides as next of kin; they act as
producers of informal care, but the disease also
has an impact on their own situation and quality of
life. Thus, it has been debated whether in addition
to assessment of their efforts in terms of contribu-
tion to informal care (as part of the numerator in
the ICER), their own quality of life/QALYs should
also be incorporated (as part of the denominator).
Although not entirely specific for AD and other
dementias, the caregiver’s situation is nevertheless
an important phenomenon, and in predementia
states, it is has been shown that the symptoms of
MCI are stressful for caregivers [59], perhaps due
to their vague nature and the uncertainty they
cause.
Other outcomes such as time to institutionaliza-
tion (‘nursing home postponement’) or time to
progression of AD/dementia have also been used
in pharmacoeconomic analyses [60]. There are two
problems with the time to institutionalization as an
outcome. First, because the cost of long-term care
is one of the major cost drivers in dementia care, it
would be part of both the numerator and denom-
inator in an estimate of the cost-effectiveness ratio;
secondly, it is extremely dependent on the avail-
ability of long-term care institutions and national
social policies. In LICs, almost no long-term care is
available.
Whether the preferences/viewpoint of the general
population or the patients and/or their next of kin/
caregivers or others should be the basis for selec-
tion of outcomes in a wide context or in the
construction of quality of life instruments is
debated; this discussion will of course have an
impact on the selection of outcomes and on how
policy and decision-makers act [61]. A patient may
regard loss of cognition and loss of autonomy as
the worst outcomes, whereas the caregiver may
consider the patient′s behavioural problems or loss
of ADL more important, and the budget holder may
be most concerned with the time to institutional-
ization. Furthermore, a policymaker may regard
quality of life as the most relevant outcome whilst
the views within a general population may vary
greatly depending on individuals’ age, life situation
and other factors. The complex interaction between
self-rated and proxy-rated quality of life is illus-
trated in the study by Jonsson et al. [62] in which
patients themselves rated their quality of life higher
than their next of kin/caregivers.
Long-term outcomes and mortality
In most reported trials (mainly on cholinesterase
inhibitors) in AD, there are either insufficient data
or no differences in mortality between treated and
nontreated patients [16, 41]. From epidemiological
research, it is known that cognitive impairment,
AD and dementias shorten life [63] and at least
some dementias can be viewed as part of terminal
decline [64]. Thus, it is logical to consider that
interventions that alter the course of disease also
will have an impact on survival. There are several
reasons why such an effect has not been shown
previously: earlier interventions have only been
symptomatic and not disease modifying, the dura-
tion of studies was too short to show effects on
mortality and selection bias was present in trials
(younger and more healthy), as mentioned above.
Patients with AD may live with the disease for
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several years and perhaps decades if the preclinical
stages are taken into consideration. Thus, it is very
difficult to draw any conclusions about effects on
survival from clinical trials lasting for short periods
(1–2 years). In a chronic progressive disorder such
as AD, modelling the long-term consequences of
intervention is unavoidable as no RCT will capture
all events and record all costs and health-related
quality of life effects over the lifetime of the patient.
This is particularly true for interventions in the
early stages of the disease, where evaluations will
need to combine short-term clinical trial data with
long-term disease progression through a disease-
modelling framework.
Conclusions
An integrated approach that combines available
evidence from population and clinical settings is
needed to help model the uncertainties of each type
of study design. This should provide a guide as to
the likely costs and benefits of particular
approaches to dementia both now and in the
future. Specifically, the following are required.
Firstly, long-term population-based data on dis-
ease progression, costs and quality of life outcomes
in clinical practice starting not only in dementia
but also in predementia states; secondly, reliable
surrogate end-points in clinical trials that are
sensitive enough to detect effects even in prede-
mentia states; thirdly, robust and validated mod-
elling methods starting from predementia states
and taking into account comorbidities and age,
and finally, a discussion of the ethical conse-
quences of early diagnosis.
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